Basiliximab Combined With Ruxolitinib as Second-line Treatment of Grade 3-4 Steroid-resistant aGVHD

NCT05021276 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Safety and Efficacy

Interventions

DRUG: Ruxolitinib

Sponsor

The First Affiliated Hospital of Soochow University

Collaborators

[object Object]
[object Object]